Evidence map›Paper›PMID 39767174›Full record

ArticleDiagnostics (Basel, Switzerland)2024

A Machine Learning Model for the Prediction of No-Reflow Phenomenon in Acute Myocardial Infarction Using the CALLY Index.

Halil Fedai, Gencay Sariisik, Kenan Toprak, Mustafa Beğenç Taşcanov, Muhammet Mucip Efe, Yakup Arğa, Salih Doğanoğulları, Sedat Gez, Recep Demirbağ

Registry-linked trialAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07203573 (Prognostic Value of the C-Reactive Protein-Albumin-Lymphocyte), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07203573 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Prognostic Value of the C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index on Patients Undergoing Primary Percutaneous Coronary Intervention

TypeobservationalSponsorAssiut UniversityRan2025 to 2026Enrolled140ConditionsPrimary Percutaneous Coronary Intervention
3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Halil FedaiDepartment of Cardiology, Harran University Faculty of Medicine, Şanlıurfa 63300, Turkey.
Gencay SariisikDepartment of Industrial Engineering, Harran University Faculty of Engineering, Şanlıurfa 63300, Turkey.ORCID 0000-0002-1112-3933
Kenan ToprakDepartment of Cardiology, Harran University Faculty of Medicine, Şanlıurfa 63300, Turkey.ORCID 0000-0001-8923-8709
Mustafa Beğenç TaşcanovDepartment of Cardiology, Harran University Faculty of Medicine, Şanlıurfa 63300, Turkey.ORCID 0000-0002-9008-6631
Muhammet Mucip EfeClinic of Cardiology, Siverek State Hospital, Şanlıurfa 63700, Turkey.
Yakup ArğaClinic of Cardiology, Viranşehir State Hospital, Şanlıurfa 63700, Turkey.
Salih DoğanoğullarıDepartment of Cardiology, Harran University Faculty of Medicine, Şanlıurfa 63300, Turkey.
Sedat GezDepartment of Cardiology, Harran University Faculty of Medicine, Şanlıurfa 63300, Turkey.
Recep DemirbağDepartment of Cardiology, Harran University Faculty of Medicine, Şanlıurfa 63300, Turkey.ORCID 0000-0001-7831-2715

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute myocardial infarction (AMI) constitutes a major health problem with high mortality rates worldwide. In patients with ST-segment elevation myocardial infarction (STEMI), no-reflow phenomenon is a condition that adversely affects response to therapy. Previous studies have demonstrated that the CALLY index, calculated using C-reactive protein (CRP), albumin, and lymphocytes, is a reliable indicator of mortality in patients with non-cardiac diseases. The objective of this study is to investigate the potential utility of the CALLY index in detecting no-reflow patients and to determine the predictability of this phenomenon using machine learning (ML) methods.

methodsThis study included 1785 STEMI patients admitted to the clinic between January 2020 and June 2024 who underwent percutaneous coronary intervention (PCI). Patients were in no-reflow status, and other clinical data were analyzed. The CALLY index was calculated using data on patients' inflammatory status. The Extreme Gradient Boosting (XGBoost) ML algorithm was used for no-reflow prediction.

resultsNo-reflow was detected in a proportion of patients participating in this study. The model obtained with the XGBoost algorithm showed high accuracy rates in predicting no-reflow status. The role of the CALLY index in predicting no-reflow status was clearly demonstrated.

conclusionsThe CALLY index has emerged as a valuable tool for predicting no-reflow status in STEMI patients. This study demonstrates how machine learning methods can be effective in clinical applications and paves the way for innovative approaches for the management of no-reflow phenomenon. Future research needs to confirm and extend these findings with larger sample sizes.

Indexed as

acute myocardial infarctionCALLY indexcardiovascular diseasesmachine learningno-reflowSTEMIXGBoost

Identifiers

PMID39767174
PMCPMC11674398

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.